Abstract
Insomnia is a significant public health concern that has prompted substantial efforts to develop treatment and management strategies. A significant proportion of complaints of insomnia are related to psychiatric conditions such as anxiety disorders and depression, and treatments for these disorders are known to exert both direct and indirect benefits on sleep as well as some negative effects on sleep and sleep physiology. Insomnia is also a prominent symptom of a number of other psychiatric disorders, including schizophrenia and bipolar disorder. The observed impact of a variety of psychiatric medications on insomnia has prompted an empirically derived practice of treating non-psychiatric disorder-related insomnia with psychiatric medications by clinicians searching for alternatives to established medication treatments for primary insomnia. This article aims to review the evidence of the impact of psychiatric medications on sleep physiology, sleep disorders in psychiatric conditions, and on primary sleep disorders. The potential for exploiting the relevant pharmacological mechanisms of action in drug development for primary insomnia will be addressed as well.
Keywords: Insomnia, antidepressants, antipsychotics, anticonvulsants, psychiatry, drug development
CNS & Neurological Disorders - Drug Targets
Title: Effects of Psychiatric Medications on Sleep and Sleep Disorders
Volume: 6 Issue: 1
Author(s): Nicholas A. DeMartinis and Andrew Winokur
Affiliation:
Keywords: Insomnia, antidepressants, antipsychotics, anticonvulsants, psychiatry, drug development
Abstract: Insomnia is a significant public health concern that has prompted substantial efforts to develop treatment and management strategies. A significant proportion of complaints of insomnia are related to psychiatric conditions such as anxiety disorders and depression, and treatments for these disorders are known to exert both direct and indirect benefits on sleep as well as some negative effects on sleep and sleep physiology. Insomnia is also a prominent symptom of a number of other psychiatric disorders, including schizophrenia and bipolar disorder. The observed impact of a variety of psychiatric medications on insomnia has prompted an empirically derived practice of treating non-psychiatric disorder-related insomnia with psychiatric medications by clinicians searching for alternatives to established medication treatments for primary insomnia. This article aims to review the evidence of the impact of psychiatric medications on sleep physiology, sleep disorders in psychiatric conditions, and on primary sleep disorders. The potential for exploiting the relevant pharmacological mechanisms of action in drug development for primary insomnia will be addressed as well.
Export Options
About this article
Cite this article as:
DeMartinis A. Nicholas and Winokur Andrew, Effects of Psychiatric Medications on Sleep and Sleep Disorders, CNS & Neurological Disorders - Drug Targets 2007; 6 (1) . https://dx.doi.org/10.2174/187152707779940835
DOI https://dx.doi.org/10.2174/187152707779940835 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Targeted Therapies for Thyroid Cancer
Current Genomics Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Dietary Antioxidants: Immunity and Host Defense
Current Topics in Medicinal Chemistry Drug Delivery Systems Using Immobilized Intact Liposomes: A Comparative and Critical Review
Current Drug Delivery Paradigm Shifts in our Views on Inclusion Bodies
Current Biochemical Engineering (Discontinued) Truly “Rational” Polytherapy: Maximizing Efficacy and Minimizing Drug Interactions, Drug Load, and Adverse Effects
Current Neuropharmacology Potential Anti-Catabolic and Anabolic Properties of Strontium Ranelate
Current Molecular Pharmacology An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Central Nervous System Agents in Medicinal Chemistry Natural and Synthetic Iminosugars as Carbohydrate Processing Enzyme Inhibitors for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy
CNS & Neurological Disorders - Drug Targets Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study
Current Vascular Pharmacology Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men
Current Pharmaceutical Design Serotonergic Modulation of Spinal Sensory Circuits
Current Topics in Medicinal Chemistry Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Dangerous Liaisons between Beta-Amyloid and Cholinergic Neurotransmission
Current Pharmaceutical Design The Differential Diagnosis of Multiple Sclerosis Using Convex Combination of Infinite Kernels
CNS & Neurological Disorders - Drug Targets Copper-Catalyzed Direct Oxidative α-Arylation of Pyrrolidine with Phenols and Naphtols
Letters in Organic Chemistry Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG
Current Alzheimer Research